Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Sun Pharma

Stocks in news: Maruti Suzuki, ITC, ZEE, Persistent Systems, and Muthoot Finance

Markets extended their winning streak on Friday, supported by encouraging quarterly business updates. Nifty strengthened its bullish structure by surpassing the 200-day EMA, positioning for further gains. ITC reported a net profit drop while revenue rose, and Maruti Suzuki saw a net profit decline. Sun Pharma reported net profit growth,…

The Economic Times

Sun Pharma Q1 Results: Profit rises 27% YoY to Rs 2,895 crore; revenue climbs 10.5%

Sun Pharma Q1 Results: Sun Pharma reported a 27% YoY rise in Q1 net profit to Rs 2,895 crore, while revenue grew 10% to Rs 15,300 crore, driven by strong performance in India and its innovative medicines business despite weak US formulations sales. EBITDA rose 3% to Rs 4,418 crore.…

The Economic Times

Stocks in news: Maruti Suzuki, ITC, Vedanta, Swiggy, RIL

Indian markets traded in a narrow range, settling marginally higher with mixed cues. Maruti Suzuki, ITC, and Vedanta shares are in focus due to various news developments. Sun Pharma and Bajaj Finserv will announce their first quarter results today. Tata Steel reported a fifteen percent rise in its net profit…

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Indian pharma firms may yet survive Trump's 200% tariff bombshell

Donald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say the long-term impact may be limited. India's cost advantage, America's dependence on imported generics and lengthy US factory approval timelines could make large-scale manufacturing shifts difficult despite Trump's…

The Economic Times

200% Trump tariff shock? India’s cheap pills may still beat US rivals

US President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical exporters, but the country's cost advantage may help many drugs remain competitive in the US market, according to the Global Trade Research Initiative (GTRI).

The Economic Times

Sun Pharma, Cipla & other pharma stocks shed over 2% as Trump announces up to 200% tariffs on generic drugs from 2028

Pharma stocks, including Sun Pharma, Cipla, Lupin and Dr Reddy's, fell up to 2.5% after US President Donald Trump announced a phased tariff plan on imported generic drugs. While generics will remain tariff-free for two years, duties will rise to 100% from August 2028 and 200% from August 2029, weighing…

The Economic Times

Dividend alert! Last day to buy JSW Steel, Sun Pharma, 4 more stocks to earn payouts up to Rs 75

JSW Steel has fixed Tuesday as the record date for its final dividend of Rs 7.1 per share for the financial year 2026. Once approved by the shareholders during its upcoming Annual General Meeting (AGM), the said dividend will be paid within 30 days from the date of its declaration,…

The Economic Times

Read news from The Economist, FT, and more,
with one subscription

Stocks in news: HDFC Bank, Vedanta Power, YES Bank, Sun Pharma, Waaree Energies

Indian markets surged for a third straight day, buoyed by global sentiment and strong performance from heavyweight stocks like HDFC Bank and YES Bank. Analysts note a technical breakout, though resistance looms. Several companies, including Dabur India and Vedanta Power, reported positive quarterly updates, while Tata Power withdrew a controversial…

The Economic Times

Bonus issues, stock splits & dividends: Titan, JSW Steel among 49 stocks turning ex-date this week. Do you own any?

Investors must hold shares of these companies in their demat accounts on the record date to be eligible for the respective corporate actions. The list remains tentative, as more companies may announce record dates for dividends, bonus issues and stock splits during the week.

The Economic Times

Market wrap: Sensex falls 372 points, Nifty closes below 23,950; Kotak Mahindra Bank drops 3%

Indian markets ended lower as Sensex and Nifty snapped a two-session winning streak, pressured by geopolitical tensions in the Middle East and broad-based selling. While pharma outperformed, auto stocks dragged. Analysts flagged near-term volatility but maintained a constructive outlook for Nifty above key support levels amid mixed global cues.

The Economic Times

Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal Manchanda

India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and consumer healthcare. While US FDA approvals for complex generics remain a challenge, innovation and contract manufacturing offer significant future profit pools. Experts anticipate biosimilars could generate substantial revenue, and despite a slow start, GLP-1…

The Economic Times

Reliance, financials and defence top investment picks as market leadership broadens: Rahul Shah

Reliance Industries is poised for a turnaround, with strong earnings, a Jio Platforms IPO, and AI/energy investments promising significant returns. Small banks are also attractive due to improving fundamentals and valuations. While IT valuations are cheap, earnings growth is a concern. Financials, particularly large private banks and NBFCs, remain a…

The Economic Times

Stocks in news: Sun Pharma, Tech Mahindra, Tata Motors, Voltas, ONGC

Indian markets saw a dip on Friday, with IT stocks leading the decline. Analysts suggest profit-taking occurred near the 24,150 mark. Despite this, the broader recovery trend remains intact above 23,700. Several companies like Sun Pharma, Tata Motors, and ONGC are in focus due to significant business developments, including acquisitions,…

The Economic Times

Sun Pharma adds Innovcare to its fold in Rs 271.2 crore all-cash transaction

India's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash deal. This strategic move aims to bolster Sun Pharma's product offerings. Innovcare, which markets pharmaceutical drugs, nutraceuticals, and cosmeceuticals, reported steady revenue growth in recent fiscal years. The transaction, expected to…

The Economic Times

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplash

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic demand and positive global healthcare trends. Analysts see long-term growth potential from aging populations and innovation. Emerging opportunities from supply chain diversification away from China also present a positive outlook for…

The Economic Times

SBI in $1 billion funding for Sun Pharma’s US deal

State Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co. This move marks a significant step for government-run banks in financing corporate takeovers. SBI will join other global lenders in this substantial deal. The funding…

The Economic Times

Sensex falls 70 points, Nifty below 23,900 as US-Iran tensions simmer

Indian stock markets opened lower on Wednesday. Sensex and Nifty saw minor declines. Investors are watching US strikes on Iran and their effect on peace deal hopes. Broader markets are performing better. India VIX, a volatility measure, dropped. Top Sensex losers included HDFC Bank and Infosys. Sun Pharma shares led…

The Economic Times

Sun Pharma Q4 Results: Cons profit rises 26% YoY to Rs 2,714 crore; board approves Rs 5/share dividend

Sun Pharma Q4 Results: Profit after tax (PAT) fell 19% sequentially during the quarter under review from Rs 3,369 crore in Q3FY26, while revenue declined 6% from Rs 15,520 crore reported in the October-December quarter of FY26.

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sector

Bernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future growth for the Indian healthcare sector. Key drivers include AI-led innovation, incremental advancements in niche areas, and improved quality culture. Attractive valuations also support this positive outlook for the…

The Economic Times

Rahul Shah bullish on pharma, sees Sun Pharma and Aurobindo as key large-cap plays

Indian equity markets show a mixed but improving consumption trend, with selective FMCG and premium retail outperforming. Page Industries is highlighted as a strong recovery story, while Nykaa and Honasa are viewed cautiously. The pharma sector continues its outperformance, with Sun Pharma and Aurobindo Pharma looking attractive.

The Economic Times

Stocks in news: ITC, LIC, Sun Pharma, Maruti Suzuki, Fino Payments Bank

Benchmark indices experienced a negative close on Thursday, marked by volatile trade and profit booking. Analysts anticipate the Nifty to continue its consolidation between 23,200 and 23,900. Several companies, including ITC, LIC, Sun Pharma, Maruti Suzuki, and Fino Payments Bank, are in focus due to Q4 results and other developments.

The Economic Times

Sun Pharma Q4 Preview: Can Unloxcyt and speciality drugs help pharma major deliver another strong quarter?

Sun Pharma is expected to post double-digit revenue growth in Q4FY26, driven by strong performance across speciality drugs, domestic formulations, and emerging markets. Brokerages highlight US portfolio strength, new launches like Unloxcyt, and a steady margin outlook despite higher R&D spending, with EBITDA growth supported by diversified global business momentum…

The Economic Times

Jio Financial, ITC Hotels and Manappuram Finance among stocks bought and sold by mutual funds in April

Mutual funds injected Rs 30,600 crore into Indian equities in April, with significant buying in ICICI Bank, SBI, and Sun Pharma. Key reductions were observed in Wipro, HDFC Bank, and Hindalco Industries across large, mid, and smallcap segments. This active portfolio management reflects ongoing strategic shifts by fund managers.

The Economic Times

When the world's an oyster for Sun (Pharma)

Indian companies are increasingly making bold acquisitions abroad. Sun Pharma's deal signals a new era of deliberate empire-building. This shift from tentative deals to strategic bets is crucial for global relevance. Successful acquisitions require clear intent, respect for acquired assets, integration discipline, financial courage, and a long-term mindset.

Times Life

7 Things That Will Get Cheaper After Budget 2026

Most budgets promise relief. Very few actually change what you pay in real life. Budget 2026 is one of those rare ones that works quietly. There were no dramatic tax cuts, no loud announcements, and no instant price drops flashed across screens. Yet, beneath the fine print, the government made…

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.